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Abstract
In contrast to adults, meningiomas are uncommon tumors in childhood and adolescence. Whether adult and pediatric men-
ingiomas differ on a molecular level is unclear. Here we report detailed genomic analyses of 37 pediatric meningiomas by 
sequencing and DNA methylation profiling. Histologically, the series was dominated by meningioma subtypes with aggres-
sive behavior, with 70% of patients suffering from WHO grade II or III meningiomas. The most frequent cytogenetic aber-
rations were loss of chromosomes 22 (23/37 [62%]), 1 (9/37 [24%]), 18 (7/37 [19%]), and 14 (5/37 [14%]). Tumors with 
NF2 alterations exhibited overall increased chromosomal instability. Unsupervised clustering of DNA methylation profiles 
revealed separation into three groups: designated group 1 composed of clear cell and papillary meningiomas, whereas group 
2A comprised predominantly atypical meningiomas and group 2B enriched for rare high-grade subtypes (rhabdoid, chordoid). 
Meningiomas from NF2 patients clustered exclusively within groups 1 and 2A. When compared with a dataset of 105 adult 
meningiomas, the pediatric meningiomas largely grouped separately. Targeted panel DNA sequencing of 34 tumors revealed 
frequent NF2 alterations, while other typical alterations found in adult non-NF2 tumors were absent. These data demonstrate 
that pediatric meningiomas are characterized by molecular features distinct from adult tumors.
Keywords Meningioma · Methylation profile · Targeted sequencing · NF2
Introduction
Among adult patients, meningiomas represent the most 
common primary intracranial tumor, accounting for 36.6% 
of newly diagnosed primary brain tumors [17]. In contrast, 
meningiomas are rare among children and young adults, 
accounting for only 3–5% of intracranial neoplasms [16, 17].
Prior clinical and genetic studies have suggested that dif-
ferences exist between pediatric and adult meningiomas in 
regard to anatomical site and clinical behavior [20, 21, 26]. 
While the vast majority of adult patients with meningiomas 
presents with sporadic tumors, pediatric patients are more 
commonly affected by an underlying tumor predisposition 
syndrome, mainly NF2. One study showed that pediatric 
meningiomas harbored NF2 deletions frequently (82%) 
along with more aggressive histological features (high 
mitotic count, brain invasion) [21]. The same study reported 
much higher frequencies of deletions in DAL-1, 1p, and 14q 
compared to adult counterparts. Recently it was reported that 
some pediatric meningiomas may carry YAP1 fusions [35].
Due to the significant risk of underlying NF2, young 
patients presenting with a solitary meningioma should be 
referred for human genetic counseling focused on NF2 sur-
veillance including genetic testing [19] Besides sporadic and 
NF2-related meningiomas, radiation induced meningiomas 
represent another clinically distinct subset [32].
The knowledge regarding the molecular alterations in 
adult meningiomas has been increased substantially over 
the last 5 years. While the fundamental role of biallelic 
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NF2 loss in meningiomas from NF2 patients and approxi-
mately 50% of sporadic meningiomas has long been rec-
ognized [27, 28], a spectrum of recurrent oncogenic driver 
mutations including in SMO, KLF4, TRAF7, AKT1, or 
PIK3CA has more recently been identified, and are mutu-
ally exclusive with NF2 alterations. Clinically relevant 
associations between driver mutations, anatomical site 
and histological subtype have been recognized, and are 
reviewed in [23]. Some of these mutations such as in the 
SMO or AKT1 genes are now considered for molecular 
targeted therapies in case of recurrent or inoperable dis-
ease [23]. Similar to meningiomas arising in the setting of 
germline NF2 mutations, radiation induced meningiomas 
are characterized by NF2 inactivation [1]. Recently, based 
on methylation profiling six different subgroups of men-
ingiomas in adults have been introduced, which differ by 
site, histological subtype, and prognosis [31].
In contrast, studies addressing the molecular altera-
tions in pediatric meningiomas by comprehensive high-
throughput analyses are rare. One study failed to detect the 
commonly observed mutations in AKT1, SMO, KLF4, and 
TRAF7 (exon 17) by using conventional Sanger sequenc-
ing [3], and further comprehensive studies have not been 
published. Here we report the results from a comprehen-
sive analysis of 37 pediatric meningiomas, integrating 
clinicopathological with genomic data derived from DNA 
methylation profiling and targeted panel sequencing.
Materials and methods
Tumor material
We analyzed 41 samples from 37 patients with meningi-
oma (age range: 1–21 years, median age: 10 years). The 
study was approved by the local institutional review board 
of the University Hospital Magdeburg (#19/14). For 32 
patients, only formalin-fixed paraffin-embedded (FFPE) 
samples were available for histological analysis. Tumors 
were graded according to the current 2016 WHO clas-
sification of brain tumors [14]. Ki-67 proliferation index 
of the tumors was assessed immunohistochemically using 
standard procedures. Tumor localization was stratified into 
convexity, skull base, spinal, and intraventricular sites. 
Clinical information regarding NF2 status was available 
for 32 patients, seven of which met clinical diagnostic cri-
teria for NF2. Information regarding tumor recurrence was 
available for 17 patients. In four patients, prior CNS irra-
diation for tumor therapy (retinoblastoma, medulloblas-
toma, ependymoma, ALL) suggests that the meningiomas 
are secondary neoplasms.
Immunohistochemistry [tissue microarray (TMA)]
From a total of 19 cases, we generated two TMAs as previ-
ously described [18]. The following antibodies were sub-
jected to TMA samples: Akt/phospho-Akt, MAPK/phospho-
MAPK, mTOR, phospho-p70S6K, 4EBP/phospho-4EBP, 
PDGF receptor, p38MAPK, TGFβR2, E-Cadherin, and 
MMP9 (all from Cell Signaling, MA).
Sanger sequencing
DNA extracted from FFPE tissue was processed using stand-
ard procedures as previously described [42]. We analyzed 
all meningiomas for known hotspot mutations in the genes 
SMO (L412F and W535L) [4], AKT1 (E17K) [42], and 
KLF4 (K409Q) [41].
450 K methylation profiling
For methylation analysis and copy-number analysis of the 
samples, Illumina 450 k Human BeadChip (Illumina, San 
Diego, CA, USA) analyses were performed as previously 
described [38].
Panel sequencing analysis
Panel sequencing for 130 genes reported to be mutant in 
meningioma based on a literature search done in Octo-
ber, 2014 was done by applying a custom hybrid-capture 
approach (Agilent Technologies, CA, USA) as described 
previously [29]. The panel was designed to assess the fre-
quency of known mutations in the respective methylation 
classes and did not aim to detect novel mutational events.
Whole genome sequencing
DNA libraries were prepared from tumor and matched nor-
mal tissue (blood) available for five pediatric meningioma 
cases (three with recurrent tumor samples available) and 
sequenced on three lanes each on HiSeq2000 instruments 
(2 × 100 bp). DNA libraries were prepared according to 
the Illumina TruSeq Nano DNA Library protocol using 
the TruSeq DNA Nano kit (Illumina, Hayward, CA) and 
sequenced on one lane on HiSeq X (2 × 151 bp) using the 
HiSeq X Ten Reagent Kit v2.5 (both Illumina).
Alignment and detection of small variants
The raw reads were mapped to the human reference genome 
(build 37, version hs37d5), using BWA mem (version 0.7.15, 
with parameter −T 0), sorted using SAMtools (version 
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0.1.19), and duplicate reads were marked using Sambamba 
(version 0.6.5, with parameter −t 1 −l 0 –hash-table-
size = 2,000,000 –overflow-list-size = 1,000,000 –io-buffer-
size = 64). Using the tumor and corresponding matched 
normal samples, somatic small variants (SNVs and indels) 
were called using the in-house pipelines as described ear-
lier [32]. Briefly, somatic SNVs were called using SAM-
tools mpileup (version 0.1.19, with parameters −REI −q 
30 −ug) and bcftools on tumor sample and then queried in 
the control samples (with parameters −ABRI −Q 0 −q 1). 
To enable calling of variants with low allele frequency we 
disabled the Bayesian model in bcftools (by setting −p 2). 
The raw calls were annotated with ANNOVAR and many 
publicly available tracks such as 1000 Genome variants, sin-
gle nucleotide polymorphism database (dbSNP), genomic 
repeat and low complexity regions and locally available con-
trols. Confidence scores for these variants were annotated as 
described previously [11]. Indels were called using Platy-
pus (version 0.8.1, with parameters −bufferSize = 100,000 
−maxReads = 5,000,000), and were annotated similar to 
the somatic SNVs. High confidence somatic indels were 
required to have the genotype 0/0 (homozygous to refer-
ence allele) in the control sample and the platypus filter tag 
‘PASS’ or, to enable the detection of somatic variants with 
low allele frequency, pass custom filters when Platypus 
reported ‘allele bias’.
Somatic small variants misclassified as germline due to 
contamination of the matched normal samples with tumor 
DNA/cells were rescued using the in-house tool TiNDA 
(Tumor in Normal Detection Analysis). VAFs from vari-
ants which are classified as ‘germline’ (i.e. variant reads 
have been identified in both tumor and the matched normal 
sample), and which are novel or rare (minor allele frequency 
(MAF) < 0.001 in gnomAD (version 2.0.1) and not present 
in the above local control of 280 WGS samples) were clus-
tered using EM-based unsupervised clustering from Canopy 
(version 1.2.0) [10]. Clusters in which at least 85% of the 
members have a tumor variant allele frequency (VAF) of 
at least 0.01 and a matched control VAF below 0.45 were 
considered as misclassified somatic variants. These rescued 
somatic SNVs and indels were mapped to the mpileup and 
Platypus raw calls and variants with confidence score > 7 
were merged into the final somatic small variant calls. Vari-
ants in the remaining clusters were classified as rare ger-
mline and were annotated as rare high confidence germline 
variants if they had a confidence score > 7 in the correspond-
ing raw calls.
Structural variant detection
Genomic structural variants were detected using SOPHIA 
(version 34.0; https:// bitbu cket. org/ utopr ak/ sophia) as 
described earlier [32], using a background population 
database consisting of 3261 WGS controls across different 
diseases (published TCGA cohorts and published/unpub-
lished DKFZ cohorts) and sequencing technologies (100 bp 
read length Illumina HiSeq 2000/2500 and 151 bp read 
length Illumina HiSeq X) aligned using the same alignment 
settings and workflow as used in the present study. Gencode 
V19 was used for the gene annotations.
Copy number states were called and tumor purity and 
ploidy were estimated using ACEseq (Allele-specific copy-
number estimation from sequencing; https:// www. biorx iv. 
org/ conte nt/ early/ 2017/ 10/ 29/ 210807) as described previ-
ously [32]. In cases where ACEseq provides multiple purity 
and ploidy solutions, the lowest ploidy solution which 
allowed to fit the majority of genomic segments to integer 
copy numbers and which was consistent with the mutant 
allele frequency distribution of somatic SNVs was manu-
ally selected.
Statistical analyses
Statistical analyses were performed using IBM SPSS Statis-
tics, version 25 (IBM Corporation and its licensors, 1989, 
2017) with a nominal error level of 5%. According to the 
type of variables (categorial, metrical or time-to-event 
endpoints), comparisons were carried out in chi-square, 
Mann–Whitney or log rank tests. For pairwise comparisons 
with three groups, the closed testing procedure was used 
(global test followed by pairwise comparisons) in categorial 
and time-to-event data and the Kruskal–Wallis tests includ-
ing adjusted pairwise tests for metrical data. However, due 
to the limited number of available cases and the exploratory 
aim of the analyses, no adjustment for considering multiple 
endpoints has been made.
For unsupervised hierarchical clustering of 37 histologi-
cally defined pediatric meningioma and 105 reference sam-
ples, we selected the 10,000 most variably methylated CpG 
sites across the dataset according to median absolute devia-
tion. Pairwise similarity of samples was calculated using 
Euclidean distance. Clusters were then linked according to 
the Ward’s linkage method.
Results
The histological subtype distribution among the 37 pri-
mary pediatric meningiomas which were graded according 
to the 2016 WHO classification [14] of brain tumors is 
shown in Fig. 1a–c. While 30% of tumors were of WHO 
grade I, the largest group consisted of atypical WHO grade 
II meningiomas (57%). Among 5 WHO grade III menin-
giomas (14%), three tumors were rhabdoid meningiomas. 
Thus, pediatric meningiomas are predominantly character-
ized by a more aggressive histology than WHO grade I, 
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which is in contrast to their adult counterparts [23]. This 
was reflected by a relatively high proliferation activity, 
with a mean Ki-67 proliferation index of 8.3% (1–20%) 
and a mean number of mitoses per 10 HPF of 1.9 (0–20). 
Brain invasion was seen in 6/32 samples analyzed (16.2%), 
and tumor necrosis was present in 10/32 cases (27%). The 
cohort contained slightly more male (N = 20) than female 
patients (N = 17). In Fig. 1d, the time to tumor recur-
rence for patients with available follow-up information is 
shown. As shown in Fig. 1e, male patients had a trend to 
less favorable outcome than female patients (p = 0.089). 
Proliferation activity as counted by Ki-67 staining was 
significantly higher in WHO grade II and grade III tumors 
than in WHO grade I meningiomas (Fig. 1f). Except one 
patient with spinal meningioma (2.7%), 36 tumors (97.3%) 
were located intracranially. Most tumors were found at the 
convexity (N = 18, 48.6%), followed by skull base (N = 15, 
40.5%) and ventricular system (N = 3, 8.1%). Skull base 

























































































































Fig. 1  Pediatric meningiomas are aggressive tumors with uncommon 
histological features. a Examples of histological subtypes more fre-
quent among pediatric meningiomas than in adult tumors. a Clear cell 
meningioma WHO grade II. b Chordoid meningioma WHO grade 
II. c Rhabdoid meningioma WHO grade III. d Atypical meningi-
oma WHO grade II with brain invasion. Distribution by WHO grade 
(b) and histological variants (c). d, e Kaplan–Meier curves showing 
clinical characteristics of 17 pediatric meningiomas with follow-up 
data available. f Proliferation activity as determined by Ki-67 immu-
nostaining within different WHO grades. g Recurrence-free survival 
according to the tumor localization (skull base or convexity)
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localization was associated with slightly less favorable 
prognosis compared to convexity localization (p = 0.057, 
Fig. 1g).
Somatic and germline NF2 alterations are 
the dominating molecular event in pediatric 
meningiomas
In an initial attempt, we wondered whether recurrent somatic 
mutations reported to occur in adult meningiomas exclusive 
of NF2 alterations are present in pediatric meningiomas as 
well [5, 7, 25]. However, by Sanger sequencing, we did not 
detect mutations at the established hotspots in AKT1, SMO, 
KLF4 and TRAF7, suggesting different tumor drivers acting 
in this age group. This observation prompted us to further 
analyze the samples by WGS, DNA methylation profiling, 
and panel sequencing.
First, we subjected all 37 patient samples to methyla-
tion profiling and DNA copy-number analysis. The most 
frequent alteration was loss of chromosome 22 including 
the NF2 gene (N = 23, 62.2%), followed by loss of chromo-
somal material on chromosome 1 (N = 9, 24.3%), chromo-
some 18 (N = 7, 18.9%), and chromosome 14 (N = 5, 13.5%) 
(Fig. 2a–c). The distribution among the WHO grades, as 
well as between males and females is shown in Fig. 2d, e.
Because loss of chromosome 22 turned out to be the 
most frequent molecular event in our series, tumors with 
(NF2) or without (Non-NF2) alterations were compared 
(Fig. 3). Comparing the CNV profile between both groups, 
NF2-altered tumors (Fig. 3a) had a higher rate of CNVs 
than Non-NF2 tumors (Fig. 3b), irrespective of WHO grade 
(Fig. 3c). The highest frequency of CNVs among NF2-
altered tumors was found in the WHO grade II group. NF2-
altered tumors tend to have higher proliferation activity 
(Fig. 3d). In contrast to chromosomal losses, gain of chro-
mosomal material was seen infrequently. Gain of chromo-
some 11 (p = 0.042) and chromosome 21 (p = 0.015) were 
independently associated with higher tumor grading. The 
presence of tumor necrosis was significantly associated 
with gain of chromosome 13 (p = 0.024). The histological 
variant was significantly associated with gain of chromo-
some 12 (p = 0.034), showing gains in one anaplastic, one 
atypical, and one chordoid meningioma, respectively. In line 
with this, gain of chromosome 12 was additionally associ-
ated with increased number of mitoses (p = 0.09). Gain of 
chromosome 14 was associated with higher mitotic activ-
ity (p = 0.05) as well. All tumors showed an unmethylated 
MGMT promoter.
Whole genome sequencing could be performed for a total 
of five meningiomas. Three of them showed germline NF2 
alterations together with somatic loss of the second allele, 
while two cases showed somatic NF2 mutations. From three 
cases (case #3 & #8 with germline NF2 alteration, case #6 
with somatic NF2 alteration), primary and recurrent tumors 
were available for WGS as well. As shown in supplemen-
tary Figure S2, recurrent tumors were similar to the primary 
tumors with the exception that the second and third recur-
rence from tumor #8, as well as recurrence from tumor #3 
had an additional amplification of the LZTR1 gene.
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Fig. 2  Summary of copy-number variations (CNV) in pediatric men-
ingiomas derived from methylation analysis. a Representative copy-
number plot. b Summary of CNV among all 37 pediatric meningi-
omas. Frequency of the most common CNV (c), and distribution of 
CNV by WHO grade (d) and sex (e)
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Pediatric meningiomas form three distinct 
methylation groups
Next we wondered whether separate methylation groups are 
present among pediatric meningiomas. Applying a methyla-
tion profile-based brain tumor classifier [6], 35/37 (95%) 
samples were classified as meningioma. However, one case 
was classified as high-grade glioma but showed histologi-
cally features of a papillary meningioma. Another case, 
meningioma by histology as well, was classified as a des-
moplastic infantile ganglioglioma [DIGG]. Interestingly, a 
TSNE plot (Figure S6) revealed that the tumor classified as 
DIGG grouped with other meningiomas (blue arrow), while 
the papillary meningioma indeed fell into the high-grade 
glioma group (green arrow).
Unsupervised hierarchical clustering of all 37 pediatric men-
ingiomas revealed separation into three subgroups (Fig. 4a). 
On the far left, a group of six patients could be distinguished 
(group 1). Among the remaining 31 cases, two major subgroups 
were formed, consisting of 15 (group 2A) and 16 (group 2B) 
cases. Group 1 was comprised of the single papillary meningi-
oma within the series (arrow) and five clear-cell meningiomas. 
Group 2A with 15 cases consisted mainly of atypical menin-
giomas (N = 8), one clear-cell meningioma, one anaplastic, as 
well as 5 WHO grade I tumors of meningothelial, fibroblastic, 
transitional, and psammomatous variant. Group 2B compris-
ing 16 tumors covered 6 WHO grade I tumors, three rhabdoid 
meningiomas, one chordoid meningioma, and six atypical 
meningiomas (Fig. 4b). The recurrent tumors which had been 
undergone WGS grouped into group 2A.
The methylation profile-based separation into three sub-
groups prompted further comparisons between the proposed 
methylation subgroups 1, 2A and 2B. Loss of chromosome 
22 was significantly less frequent in group 2B (Fig. 4c). If 
the groups were compared regarding the clinical informa-
tion about signs of NF2, no patient from group 2B had been 
diagnosed clinically for this disease (Fig. 4d). These findings 
suggest that group 1 and 2A but not group 2B are driven by 
NF2 alterations. Additionally, group 2B showed frequent 
losses of chromosome 11  (Fig.  4e), while group 1 was 
characterized by loss of chromosome 19. The proliferation 
activity, however, was not significantly different between the 
three groups (supplementary Figure S1).
Panel sequencing
Because we initially did not detect characteristic somatic 
mutations known from adult meningiomas by Sanger 
sequencing, our cohort was further screened for mutations 
in 130 genes by panel sequencing as previously reported 
[30]. The oncoplot in Fig. 5 shows the results from 34 cases 
with sufficient material for analysis, together with clinico-
pathological data. As already suggested by the methylation 
profiling and respective copy-number data, the most frequent 
















































Fig. 3  Comparison of pediatric meningiomas with (NF2) or without (non-NF2) allelic losses at chromosome 22. Summary of CNV in cases with 
(a) or without (b) NF2-LOH. c Distribution among WHO grades. d Proliferation activity (Ki-67 labeling)
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Fig. 4  Methylation profile of 37 pediatric meningiomas. a Unsuper-
vised hierarchical clustering reveals three subgroups (1, 2A, 2B). 
Arrows indicate tumors not classified as meningioma in the meningi-
oma classifier for adult tumors. Radiation-induced pediatric meningi-
omas are marked by (*). b Relation between histological variant and 
methylation subgroup. Frequency of NF2-LOH (c) and clinical diag-
nosis of NF2 (d) among the three subgroups. e Frequency of LOH 
at chromosome 11 among the three subgroups. Note that c-e display 
data for 35 cases after exclusion of two cases (arrows) which were not 
classified as meningioma using the meningioma classifier [31]
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Fig. 5  Oncoplot summarizing relation between histological vari-
ant, WHO grade, sex, tumor localization (site), prior irradiation, and 
mutational spectrum derived from panel sequencing of 130 genes. 34 
cases were analyzed; for three cases no sufficient material was avail-
able. Arrows indicate the two samples from Fig. 4a which were not 
classified as meningioma
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alterations were occasionally found in BRCA1, RGPD3, 
APC, TSC1, and KDM6A with uncertain relevance and 
unknown germline status. All SMARCE1 alterations were 
present in clear-cell meningiomas (mutations in 5/7 tumors 
detected). No hotspot mutations found in adult meningi-
omas were detected for SMO, KLF4, and AKT1. Moreover, 
no TERT promoter mutations were detected. Additional 
immunohistochemistry for BAP1 in two of the three rhab-
doid meningiomas showed retained immunoexpression, sug-
gesting absence of BAP1 mutations (Figure S5).
Methylation profiles differ between adult 
and pediatric meningiomas
Next, we analyzed the methylation profiles from all 37 
pediatric meningiomas together with a group of 105 adult 
meningiomas which has been described in detail before [31]. 
As shown in Fig. 6, the vast majority of pediatric meningi-
omas (N = 28) again clustered into a separate group. Moreo-
ver, the three subgroups (1, 2A, 2B) defined above could 
be distinguished again. The few pediatric tumors clustering 
with adult malignant (light green) or benign NF2-mutated 
tumors (light blue) were an anaplastic meningioma, an atypi-
cal meningioma, and a fibroblastic meningioma.
Signaling pathways activated in pediatric 
meningiomas
To evaluate potential treatment targets in our cohort, we 
performed immunohistochemical analyses for several pro-
teins involved in essential cellular signaling pathways. A 
TMA containing 20 pediatric meningiomas was studied by 
Fig. 6  Unsupervised hierarchical clustering of 105 adult and 37 pediatric meningiomas. Ben-1 and Ben-2 refers to methylation subgroups of 
adult meningiomas proposed by Sahm et al. [31]
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immunohistochemistry. While for most of the proteins the 
presence or absence of expression was unrelated to clinical 
parameters or detected molecular alterations, we found that 
the expression of p38MAPK was significantly associated 
with increased mitotic activity (p = 0.036) and increased 
Ki67 proliferation index (p = 0.041) (Fig. 7a–c).
Discussion
We have performed comprehensive molecular analysis of a 
large group of pediatric meningiomas, revealing that these 
tumors are substantially different from their adult counter-
parts by means of histological subtype distribution, methyla-
tion profiles, and mutational landscape.
While meningiomas are the most frequent primary intrac-
ranial tumors in adults, they are exceptionally rare among 
children [16] and adolescents [17]. It had been already 
reported that the gender distribution is different in pedi-
atric meningiomas, with more male patients affected, and 
that the spectrum of histological variants is different [21]. 
These epidemiological data were confirmed in our series. A 
meta-analysis compiling data from 677 pediatric and ado-
lescent meningioma patients showed that patients with NF2 
had worse recurrence-free survival (RFS) time than patients 
without [12]. They also found reduced RFS in patients with 
grade III meningiomas, compared to grade I/II tumors. How-
ever, we did not see a clear reduction of the time to tumor 
recurrence in grade III meningiomas, although the number 
of cases with follow-up data available was rather small. 
In contrast, grade III meningiomas showed similar time 
to tumor recurrence as grade I meningiomas. This might 
be explained by the fact that the group of grade III tumors 
beside anaplastic meningiomas included rare meningioma 
variants like papillary or rhabdoid meningiomas, for which 
follow-up data from larger series of pediatric meningiomas 
are not available.
One of the major findings is the high frequency of chro-
mosome 22 alterations in our cohort. Alterations in the 
tumor suppressor gene NF2 located on chromosome 22q 
are the most common finding in meningiomas occuring 
in adults. Loss of heterozygosity (LOH) and inactivating 
NF2 mutations are found in 40–80%, supporting a classical 
two-hit hypothesis for meningioma development [27, 28]. 
The alterations include deletions, insertions, and mutations 
affecting splice sites, resulting in a non-functional protein 
[13]. For pediatric meningiomas, Perry et al. have reported 
a detailed analysis on NF2 in this patient group, with NF2 
deletions in 86% of NF2 patients and 70% in non-NF2 
patients [21]. We found LOH on chromosome 22 in 76% of 
samples, confirming the dominating role of this tumor sup-
pressor gene in pediatric meningiomas.
Recently, a number of Non-NF2 alterations have been 
identified in sporadic adult meningiomas (reviewed in [23]). 
The most frequent one affects the TRAF7 (TNF receptor 
associated factor) gene [7]. Less frequently, alterations in 
SMO, KLF4, AKT1, PIK3CA are detectable. In our initial 
Sanger sequencing approach we did not detect any of these 
alterations, which is in line with recent data from Battu et al. 
[3]. Recently, Toland et al. reported similar findings with 
absence of the non-NF2 alterations in pediatric meningi-
omas [39]. Together with the high frequency of NF2 altera-
tions it can be concluded that pediatric meningiomas are 
mainly driven by loss of this tumor suppressor.
TERT promoter mutations have been found in about 6% 
of adult meningiomas and were associated with higher men-
ingioma grade and early recurrence [30, 37]. Surprisingly, 
despite the high frequency of aggressive meningioma sub-



















































Fig. 7  Analysis of p38MAPK signaling in pediatric meningiomas. 
Examples of p38MAPK-immunopositive (a) and immunonegative (b) 
tumor samples derived from a tissue micro array (TMA). Pediatric 
meningiomas with activation of p38MAPK have higher proliferation 
activity (b) and mitotic count (c) compared to meningiomas without 
p38MAPK expression
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The most intriguing finding of our study was the observa-
tion that unsupervised clustering of the methylation profile 
revealed three novel subgroups. Analysis of DNA methyla-
tion to characterize brain tumors has been recently intro-
duced in molecular neuropathology as a valuable tool not 
only to support conventional histological diagnoses, but also 
to uncover biological relations between morphologically 
unrelated tumors [6]. For adult meningiomas, Sahm et al. 
have recently established a methylation-based classification 
system, separating six different methylation classes with 
distinct molecular and clinical characteristics [1]. The cur-
rent study expands this methylation-based classification to 
pediatric meningiomas, suggesting three distinct subgroups 
with separate molecular characteristics.
One group (designated group 1) covering 6 pediatric 
meningiomas was almost exclusively built by clear-cell 
meningiomas. Clear cell meningiomas are known to be 
most prevalent in pediatric and adolescent meningiomas 
[24], and their molecular basis is defined by alterations of 
the SMARCE1 tumor suppressor gene [8, 36]. Consistently, 
panel sequencing confirmed the presence of SMARCE1 
mutations in five of these tumors. In line with previous data, 
group 1 was additionally characterized by allelic losses at 
chromosome 22. Another intriguing molecular feature of 
group 1 was the high frequency of allelic losses at chromo-
some 19. This aberration has been rarely described in menin-
giomas in association with high-grade meningiomas [2, 15].
The remaining 31 pediatric meningiomas formed a large 
group which could be separated into two distinct subgroups 
designated as group 2A and 2B. Group 2A was dominated 
by atypical meningiomas WHO grade II. Interestingly, in 
this group 100% of cases showed chromosome 22 loss, as 
well as the highest frequency of clinically diagnosed NF2. 
Thus, this group can be described as the NF2-driven sub-
group of pediatric meningiomas.
The third group, designated group 2B, was characterized 
by a mixture of histological variants but included all rhab-
doid meningiomas WHO grade III. Moreover, only in this 
group allelic loss of chromosome 11 were observed, while 
loss of chromosome 22 was rare and clinical signs of NF2 
were absent. Meningiomas with rhabdoid features were ini-
tially thought to be characterized by aggressive biology [22]. 
Recently it could be shown that the clinical course of rhab-
doid meningiomas largely depends on the loss of the tumor 
suppressor BAP1, irrespective of the underlying rhabdoid 
phenotype [33, 34, 40].
YAP1 fusions have been recently reported among pedi-
atric meningiomas [35]. However, chromosomal rear-
rangement around the YAP1 locus serving as a surrogate 
for YAP1 alterations were not detected in our cohort, while 
RNA sequening would be required to address this question 
appropriately.
Another striking observation is that the methylation pro-
file of pediatric meningiomas differs clearly from the one 
observed in adult meningioma patients. By analyzing pedi-
atric and adult tumors together the pediatric group still was 
clearly separated. Despite the high frequency of NF2 altera-
tions in the pediatric group, the tumors did not fall into the 
cluster of NF2-altered adult meningiomas. This indicates 
that the underlying biology is substantially different between 
pediatric and adult meningiomas.
The lack of NF2 patients being represented in the 2B 
methylation cluster could have clinical implications. While 
approximately 40% of young patients presenting with a soli-
tary meningioma have an underlying germline NF2 muta-
tion, the diagnosis can be difficult to ascertain genetically 
due to mosaic status and may require years to confirm clini-
cally [19]. Moreover, in our retrospective series it appeared 
difficult to trace back clinical features according to the 
consensus criteria [9]. If our findings can be confirmed in 
a larger cohort of NF2 meningioma patients, methylation 
profiling could provide a valuable diagnostic adjunct.
Taken together, our data show that pediatric meningiomas 
can be separated into groups with distinct morphological 
and molecular features, and that pediatric meningiomas are 
distinct from adult counterparts despite sharing a high fre-
quency of NF2 alterations. However, compared with adult 
counterparts and the well-established methylation classes 
with clear prognostic implications [31], for pediatric men-
ingiomas the establishment of prognostic groups based on 
the methylation classification appears less likely, given the 
low frequency of meningiomas in this age group.
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